Alexion Pharma

Wilson Therapeutics is a biopharmaceutical company based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology and Wilson's disease, as well as some other clinical pathologies.

Wilson Therapeutics

Synageva was a publicly listed biopharmaceutical company headquartered in Lexington, Massachusetts dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. The company had manufacturing and laboratory locations in Lexington and Holden, Massachusetts, Bogart and Athens Georgia, as well as offices in a variety of locations around the world.

Synageva

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).  In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Alexion (ALXN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Alexion (ALXN) Catches Eye: Stock Jumps 7.8%

Amgen

Biotech companies Amgen and Alexion Pharmaceuticals reportedly reached an agreement in a patent battle over blockbuster rare-disease drug Soliris. ALXN stock popped Thursday.

Alexion Jumps After Reportedly Settling Amgen Patent Battle

Workday

Stocks in the Nasdaq were generally higher, but these two stood out.

Nasdaq Today: Why Alexion and Workday Stock Are Soaring

Intuitive Surgical

Livongo Health Inc

These healthcare stocks are already dominant, and it should remain that way for a long time to come.

3 Healthcare Stocks With Sustainable Competitive Advantages

Alexion Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
The post Alexion Stock Shows Rising Strength On Strong Earnings, Expansion Deals appeared first on Investor's Business Daily.

Alexion Stock Shows Rising Strength On Strong Earnings, Expansion Deals

Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) were up fractionally on Tuesday after activist investment frim Elliot Advisors again called for a company sale.

Hedge Fund Tells Alexion Management to Sell Company

Alexion Pharmaceuticals (NASDAQ: ALXN) shares are trading higher on Tuesday, on a report that Elliott Advisors sent a letter to the company seeking an immediate expiration of sales.

Why Alexion's Stock Is Trading Higher Today

Booking Hlds

Danaher

Dunkin' Brands

Knowles

Lam Research

Mastercard

MercadoLibre

Ken Fisher (Trades, Portfolio), founder of Fisher Asset Management, bought shares of the following stocks in both the fourth quarter of 2019 and the first quarter of 2020.

8 Stocks Ken Fisher Continues to Buy

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Alexion Pharmaceuticals (ALXN) Stock Undervalued Right Now?

Alexion Pharmaceuticals, Inc. (ALXN) CEO Ludwig Hantson on Q1 2020 Results - Earnings Call Transcript

Alexion (ALXN) beats on earnings and sales in the first quarter of 2020 but lowers view due to the ongoing pandemic.

Alexion (ALXN) Beats on Q1 Earnings & Sales, Lowers Guidance

Avid Technology

B2Gold

CURO Group Hlds

Cassava Sciences Inc

If other factors are constant while comparing stocks, the one with a higher earnings yield has the potential to provide comparatively greater returns.

Add Value to Your Portfolio With 5 High Earnings Yield Picks

Alexion (ALXN) delivered earnings and revenue surprises of 19.26% and 6.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Alexion Pharmaceuticals (ALXN) Tops Q1 Earnings and Revenue Estimates

Alexion earnings easily beat first-quarter estimates, but the biotech giant trimmed full-year targets. ALXN stock was not yet active early Wednesday.

Alexion Earnings Top But Biotech Cuts 2020 Guidance

Alexion Pharmaceuticals (NASDAQ: ALXN) shares are trading lower on Tuesday, after the company reported the purchase of Portola Pharma for $18 per share in cash.

Why Alexion's Stock Is Trading Lower Today

ACADIA Pharma

Allogene Therapeutics Inc

Alnylam Pharmaceuticals

Horizon Pharma

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates

Portola Pharmaceuticals

Alexion Pharmaceuticals pledged to buy Portola Pharmaceuticals on Tuesday in a deal that combines two blood disease-focused biotech companies. Alexion stock slipped, but Portola stock flew.

Biotech Giant Alexion Swipes Blood Disease-Focused Portola In Buyout

Shares of Portola Pharmaceuticals Inc. PTLA, +129.38% more than doubled in very active morning trading Tuesday, after the biopharmaceutical company focused on life-threatening blood-related disorders announced a deal to be acquired by Alexion Pharmaceuticals Inc.

Portola's stock more than doubles on heavy volume after Alexion buyout deal

Large-cap biopharma Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced a deal Tuesday to buy its small-cap peer Portola Pharmaceuticals Inc (NASDAQ: PTLA).

What You Should Know About Alexion's $1.4B Proposed Buyout Of Portola Pharma

Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Alexion (ALXN) Ahead of Earnings?

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again

Investors will focus on the performance of Soliris and Ultomiris along with other pipeline updates, when Alexion (ALXN) reports first-quarter 2020 results.

Will Soliris & Ultomiris Drive Alexion's (ALXN) Q1 Earnings?

In the latest trading session, Alexion Pharmaceuticals (ALXN) closed at $107.47, marking a -0.9% move from the previous day.

Alexion Pharmaceuticals (ALXN) Stock Moves -0.9%: What You Should Know

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth

Pinterest

Block

It doesn't take a fortune to make money in the stock market.

News for Alexion Pharma Stock (ALXN)